Calithera Biosciences Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Calithera Biosciences stock.
View analyst ratings for Calithera Biosciences or view top-rated stocks.

Wall Street analysts have given Calithera Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Calithera Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Calithera Biosciences saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 2,660,000 shares, an increase of 35.0% from the July 29th total of 1,970,000 shares. Based on an average daily trading volume, of 826,800 shares, the days-to-cover ratio is currently 3.2 days. Currently, 3.9% of the shares of the stock are short sold.
View Calithera Biosciences' Short Interest.

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Calithera Biosciences.

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.05. The biotechnology company earned $3 million during the quarter.
View Calithera Biosciences' earnings history.

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CALA stock has decreased by 56.8% and is now trading at $2.26.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1-year price targets for Calithera Biosciences' shares. Their forecasts range from $2.00 to $5.00. On average, they anticipate Calithera Biosciences' stock price to reach $3.67 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts' price targets for Calithera Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Calithera Biosciences include Silence Therapeutics (SLN), Pharming Group (PHAR), Xenon Pharmaceuticals (XENE), Rigel Pharmaceuticals (RIGL), Seres Therapeutics (MCRB), Imago BioSciences (IMGO), G1 Therapeutics (GTHX), Affimed (AFMD), Spero Therapeutics (SPRO), Rhythm Pharmaceuticals (RYTM), Pliant Therapeutics (PLRX), Adagene (ADAG), Albireo Pharma (ALBO), DiaMedica Therapeutics (DMCAF) and Altimmune (ALT).
View all of CALA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (13.97%), BVF Inc. IL (9.85%), Vanguard Group Inc. (3.96%), BlackRock Inc. (3.77%), Dimensional Fund Advisors LP (1.85%) and Millennium Management LLC (1.64%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong and Value Fund L P Biotechnology.
View institutional ownership trends for Calithera Biosciences.

CALA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Susquehanna International Group LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Calithera Biosciences or view top insider-selling stocks.

CALA stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Morgan Stanley, Morgan Stanley, Millennium Management LLC, Ergoteles LLC, Bridgeway Capital Management LLC, Renaissance Technologies LLC, and Walleye Capital LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Calithera Biosciences or or view top insider-buying stocks.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CALA stock can currently be purchased for approximately $2.26.

Calithera Biosciences has a market capitalization of $167.50 million and generates $22.25 million in revenue each year. The biotechnology company earns $-90,140,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

Calithera Biosciences employs 93 workers across the globe.

The official website for Calithera Biosciences is www.calithera.com.

Calithera Biosciences is headquartered at 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected].